Abstract：Renal cell carcinoma is one of the most common urological malignancies. Molecular targeted therapy is the main treatment formetastatic renal cell carcinoma at present. By targeting specificspot and signaling pathways, targeted therapy can inhibit the proliferation of tumor cells and then exert the function of anti-tumor on the basis of differences between tumor tissue and normal tissue in the aspect of molecular biology such as genes, signal transduction. This review mainly summarizes current status and progress of molecular targeted drug therapy in the treatment of metastatic renal cell carcinoma.
张帆,郭刚,李新涛,陈路遥,张旭. 转移性肾细胞癌的分子靶向药物治疗现状及进展[J]. 微创泌尿外科杂志, 2017, 6(2): 113-118.
Zhang Fan, Guo Gang, Li Xintao, Chen Luyao, Zhang Xu. Current status and progress of molecular targeted drug therapy in metastatic renal cell carcinoma. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2017, 6(2): 113-118.
[1]Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med, 2005,353(23):2477-2490. [2]Lindblad P. Epidemiology of renal cell carcinoma. Scand J Surg, 2004,93(2):88-96. [3]Basso M, Cassano A, Barone C. A survey of therapy for advanced renal cell carcinoma. Urol Oncol, 2010,28(2):121-133. [4]Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol, 1995,154(1):28-31. [5]Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet, 2009,373(9669):1119-1132. [6]Zimmer M, Doucette D, Siddiqui N, et al. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res, 2004,2(2):89-95. [7]Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res, 2003,9(1):327-337. [8]Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol, 2004,22(3):454-463. [9]Polyzos A. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J Steroid Biochem Mol Biol, 2008,108(3-5):261-266. [10]Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007,356(2):115-124. [11]Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol, 2009,10(8):757-763. [12]吴翔,李学松,黄立华,等.舒尼替尼治疗转移性肾癌的疗效和安全性分析:单中心37例总结.中华泌尿外科杂志,2011,32(4):278-281. [13]de Groot S, Redekop WK, Sleijfer S, et al. Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: Results from a population-based registry. Urology, 2016,95:121-127. [14]Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004,64(19):7099-7109. [15]Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007,356(2):125-134. [16]Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009,27(8):1280-1289. [17]胡岚亭,张奇夫,姜有涛,等.索拉非尼治疗晚期肾癌33例临床分析.中华泌尿外科杂志,2011,32(7):494-496. [18]赵欣,寿建忠,周爱萍,等.索拉非尼治疗晚期肾癌临床观察.中华泌尿外科杂志,2010,31(1):8-11. [19]Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res, 1997,57(20):4593-4599. [20]Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 2007,370(9605):2103-2111. [21]Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol, 2008,26(33):5422-5428. [22]Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol, 2010,28(13):2144-2150. [23]Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol, 2010,28(3):475-480. [24]Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol, 2010,28(6):1061-1068. [25]Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res, 2008,14(22):7272-7283. [26]Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol, 2007,8(11):975-984. [27]Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet, 2011,378(9807):1931-1939. [28]Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol, 2002,20(1):289-296. [29]Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med, 2007,356(22):2271-2281. [30]Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol, 2009,26(2):202-209. [31]Amato RJ, Jac J, Giessinger S, et al. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer, 2009,115(11):2438-2446. [32]Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 2008,372(9637):449-456. [33]Guo J, Huang Y, Zhang X, et al. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study. BMC Cancer, 2013,13:136. [34]Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet, 2007,370(9604):2011-2019. [35]Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst, 2007,99(1):81-83. [36]Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer, 2010,116(18):4256-4265. [37]Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol, 2008,53(5):917-930. [38]司倩,刘相端,梅家转.肾癌患者口服依维莫司片致急性肾功能不全1例探讨.肿瘤,2015,35 (12):1401-1403. [39]张帆,郭刚,何学酉,等.依维莫司二线治疗转移性肾细胞癌的疗效及安全性观察:单中心7例报告.临床泌尿外科杂志,2015,30(10):902-905. [40]Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009,27(22):3584-3590. [41]Domagala-Haduch M, Cedrych I, Jasiowka M, et al. Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma. Arch Med Sci, 2016,12(2):360-364. [42]Wells JC, Stukalin I, Norton C, et al. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol, 2016,S0302-2838(16):30258-30265.
